Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giandomenico Roviello

Showing results (1-10 of 344) with videos related to

Pageof 35
Sort By:
Oncotargets and Therapy|September 15, 2015
The distinctive nature of adenocarcinoma of the lungGiandomenico Roviello
JAMA Oncology|September 11, 2025
Integrating Oncology Lessons Across Tumor Types From Kidney to Prostate-A Good-Risk ShiftGiandomenico Roviello
The International Journal of Biological Markers|September 2, 2017
Role of PSA response as a marker for efficacy of patients with castration-resistant prostate cancer treated with novel hormonal therapiesGiandomenico Roviello
The Lancet. Oncology|November 27, 2025
The paradox of generics: broader access, less freedomGiandomenico Roviello
European Urology Oncology|July 29, 2025
Re: Rohan Garje, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, et al. Systemic Therapy in Patients with Metastatic Castration-resistant Prostate Cancer: ASCO Guideline Update. J Clin Oncol 2025;43:2311-34Giandomenico Roviello
European Urology|September 28, 2025
Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.07.002Giandomenico Roviello, Lorenzo Antonuzzo
Current Cancer Drug Targets|November 10, 2015
Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?Giandomenico Roviello, Daniele Generali
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|July 21, 2020
How the CARD trial has changed the cards on the table for metastatic castration resistant prostate cancerGiandomenico Roviello, Benedetta Panella
Frontiers in Oncology|December 26, 2022
Editorial: Microbiota and metabolites in cancer immunotherapyGiandomenico Roviello, Martina Catalano
Clinical Genitourinary Cancer|March 5, 2019
New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, WhenGiandomenico Roviello, Daniele Generali
Pageof 35

Showing results (1-10 of 344) with videos related to

Sort By:
Pageof 35
Oncotargets and Therapy|September 15, 2015
The distinctive nature of adenocarcinoma of the lungGiandomenico Roviello
JAMA Oncology|September 11, 2025
Integrating Oncology Lessons Across Tumor Types From Kidney to Prostate-A Good-Risk ShiftGiandomenico Roviello
The International Journal of Biological Markers|September 2, 2017
Role of PSA response as a marker for efficacy of patients with castration-resistant prostate cancer treated with novel hormonal therapiesGiandomenico Roviello
The Lancet. Oncology|November 27, 2025
The paradox of generics: broader access, less freedomGiandomenico Roviello
European Urology Oncology|July 29, 2025
Re: Rohan Garje, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, et al. Systemic Therapy in Patients with Metastatic Castration-resistant Prostate Cancer: ASCO Guideline Update. J Clin Oncol 2025;43:2311-34Giandomenico Roviello
European Urology|September 28, 2025
Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.07.002Giandomenico Roviello, Lorenzo Antonuzzo
Current Cancer Drug Targets|November 10, 2015
Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?Giandomenico Roviello, Daniele Generali
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|July 21, 2020
How the CARD trial has changed the cards on the table for metastatic castration resistant prostate cancerGiandomenico Roviello, Benedetta Panella
Frontiers in Oncology|December 26, 2022
Editorial: Microbiota and metabolites in cancer immunotherapyGiandomenico Roviello, Martina Catalano
Clinical Genitourinary Cancer|March 5, 2019
New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, WhenGiandomenico Roviello, Daniele Generali
Pageof 35